These compounds are: (i) Briciclib, Prexasertib, AHPN, and IMD-0354 which have been not yet been analyzed in the context of ADPKD; (ii) Cytarabine, Ancitabine, Clofarabine, Gemcitabine, Adefovir, and Topotecan, Belotecan, and 9-Methoxycamptothecin, which inhibit the proliferation of Pkd1−/− cells by directly interfering with DNA replication; (iii) Combretastatin A-4, Leptomycin B, Delanzomib, CB30865, Cerivastatin, and Pitavastatin which have been previously proposed as potential therapeutic options for ADPKD (142–144). The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.